A Phase 1b/2, multicenter, randomized, open-label
study to evaluate the efficacy and safety of
GSK5764227 alone and in combination in
participants with previously treated advanced
unresectable or metastatic gastrointestinal solid
tumors
This study will check how well a new medicine, GSK5764227, works, how safe it is and howthe body handles it in participants all around the world with advanced inoperable ormetastatic gastrointestinal cancer who have previously received treatment.
